Sacubitril + valsartan + dapagliflozin

  • 1 lab in 1 country
  • Funder: Ministero dell’Istruzione, dell’Università e della Ricerca
  • 2 of 2 findings with company ties
  • Animals1

Outcomes

2

Cellular senescence

downin rats1

1 study
  1. Sacubitril + valsartan + dapagliflozin decreases cellular senescence in rats.

    “The benefit of S/V + D was associated with reactivation of the Nrf2/Keap1 and the AMPK/NAMPT/SIRT axes and reduced markers of cellular senescence”

    Animalsmodel of dysmetabolic aging heart failureheart45 weeksfemales

    Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction

    Cardiovascular diabetology21 Mar 2026

More on Cellular senescence

Diastolic function

upin rats1

1 study
  1. Sacubitril + valsartan + dapagliflozin improves diastolic function in rats.

    “S/V + D combination further improved diastolic function, reduced left ventricular filling pressures, and enhanced chamber compliance.”

    Animalsmodel of dysmetabolic aging heart failureheart45 weeksfemales

    Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction

    Cardiovascular diabetology21 Mar 2026

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 months